VELETRI Global Market Report 2025

The VELETRI market size has grown strongly in recent years. It will grow from $1.34 billion in 2024 to $1.45 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historical period can be attributed to several factors, including the rising prevalence of pulmonary arterial hypertension (PAH), greater awareness of the condition, an expanding elderly population, global increases in lifestyle-related health issues, and higher healthcare expenditure.

The VELETRI market size is expected to see strong growth in the next few years. It will grow to $1.95 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period can be attributed to the rising prevalence of venous diseases, increased awareness and early diagnosis, higher spending on chronic diseases, improved healthcare infrastructure, and a growing patient population. Key trends in this period include technological advancements, collaborations between pharmaceutical companies and research institutions, a strong pipeline of clinical research, an increase in R&D activities, and the emergence of biosimilars and generics.

The growing prevalence of pulmonary arterial hypertension (PAH) is expected to drive the expansion of the VELETRI market in the future. PAH is a rare, progressive disease characterized by high blood pressure in the lung arteries, which can lead to heart failure if left untreated. The increasing prevalence of PAH is due to factors such as enhanced diagnostic techniques, an aging population, and heightened awareness of the condition. VELETRI is used to treat PAH by improving exercise capacity and slowing disease progression through vasodilation. For example, in October 2022, the American College of Cardiology Foundation, a US-based nonprofit medical society, reported that PAH affects approximately 15 to 30 people per million. As the prevalence of PAH rises, the demand for VELETRI is expected to grow.

The growing incidence of venous diseases is also expected to drive the VELETRI market forward. Venous diseases occur when veins experience impaired blood flow, resulting in symptoms such as swelling, pain, and potential complications such as varicose veins and deep vein thrombosis. The increasing prevalence of venous diseases is influenced by factors such as an aging population, sedentary lifestyles, obesity, and better diagnostic capabilities. VELETRI is used to improve exercise capacity and alleviate symptoms in patients with venous diseases affecting the pulmonary vasculature. For instance, in January 2025, the Centers for Disease Control and Prevention (CDC) reported that venous thromboembolism (VTE), which causes blood clots, impacts up to 900,000 people annually in the United States, with an estimated 60,000 to 100,000 deaths linked to VTE each year. As venous diseases continue to rise, the VELETRI market will likely grow.

Rising healthcare spending is also expected to fuel the demand for VELETRI. The increase in healthcare expenditure is driven by factors such as aging populations, advanced medical technologies, a rise in chronic diseases, and higher drug and treatment costs. The growth in healthcare spending ensures the affordability, accessibility, and continued research of VELETRI, making it available for PAH patients who require long-term intravenous therapy. For instance, in November 2024, Eurostat, a Luxembourg-based governmental organization, reported that healthcare expenditure in Europe rose from $1.69 trillion in 2021 to $1.75 trillion in 2022, marking a 3.6% increase. This growing healthcare investment is expected to further drive the expansion of the VELETRI market.

Major players in the VELETRI market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Actelion Pharmaceuticals Ltd., Euroapi S.A., United Therapeutics Corporation, Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Meitheal Pharmaceuticals Inc., Smiths Medical, and Guangzhou Tosun Pharmaceutical Co. Ltd.

North America was the largest region in the VELETRI market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in VELETRI report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the VELETRI market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

VELETRI (epoprostenol) is a prostacyclin vasodilator used to treat pulmonary arterial hypertension (PAH). It works by relaxing blood vessels and improving blood flow, which helps lower blood pressure in the lungs. Unlike Flolan, VELETRI does not require refrigeration, making it more convenient for continuous infusion. It is administered intravenously to enhance exercise capacity and alleviate symptoms in PAH patients.

The primary types of VELETRI are injectable and inhalation. The injectable form is a prostacyclin (epoprostenol) therapy used to treat pulmonary arterial hypertension (PAH), improving both exercise capacity and symptoms. It has various applications, including PAH and other conditions, and is distributed through a range of channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The VELETRI market research report is one of a series of new reports that provides VELETRI market statistics, including the VELETRI industry global market size, regional shares, competitors with the VELETRI market share, detailed VELETRI market segments, market trends, and opportunities, and any further data you may need to thrive in the VELETRI industry. This VELETRI market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The VELETRI market consists of sales of injections, biosimilars, infusion systems, and related equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.